Experimental drug SHR-A1904 takes on Hard-to-Treat colorectal cancer

NCT ID NCT07700719

Not yet recruiting Disease control Sponsor: Peking University Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This phase 2 trial tests an experimental drug called SHR-A1904 in people with advanced colorectal cancer that has spread and no longer responds to standard treatments. The study aims to see if the drug is safe and can shrink tumors or slow the disease. Participants must have already tried at least two lines of standard chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called SHR-A1904
What this could lead to: If it works, this could offer a new treatment option for people with advanced colorectal cancer who have run out of standard therapies.
What could go wrong: This is a small, early-phase study with only 17 participants, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER METASTATIC

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Peking University cancer hospital

Beijing, Beijing Municipality, 100142, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.